
Inspire basic results report

1. Participant Flow



2. Baseline Characteristics

Table 1 Patient demography by trial allocation

		Usual Care (n=82)	Low IMT (n=84)	High IMT (n=171)	Overall (n=337)
BASELINE CHARACTERISTICS					
Sex	Male	54/82 (65.9%)	50/84 (59.5%)	97/171 (56.7%)	201/337 (59.6%)
	Female	28/82 (34.1%)	34/84 (40.5%)	74/171 (43.3%)	136/337 (40.4%)
Age at randomisation (years) – median (IQR)		69.0 (63.0, 75.0)	68.5 (61.0, 73.5)	67.0 (58.0, 74.0)	68.0 (60.0, 74.0)
Body mass index ^a		27.4 (5.8)	27.1 (5.1)	27.5 (5.1)	27.3 (5.3)
Ethnicity	Other ethnic group	2/82 (2.4%)	1/82 (1.2%)	1/170 (0.6%)	4/334 (1.2%)
	White or caucasian	74/82 (90.2%)	78/82 (95.1%)	162/170 (95.3%)	314/334 (94.0%)
	Black/Black British	1/82 (1.2%)	2/82 (2.4%)	4/170 (2.4%)	7/334 (2.1%)
	Mixed/Multiple ethnic groups	2/82 (2.4%)	0/82 (0.0%)	0/170 (0.0%)	2/334 (0.6%)
	Asian/Asian British	3/82 (3.7%)	1/82 (1.2%)	3/170 (1.8%)	7/334 (2.1%)
Type of surgery	Cardiac	9/82 (11.0%)	10/84 (11.9%)	20/171 (11.7%)	39/337 (11.6%)
	Abdominal	72/82 (87.8%)	73/84 (86.9%)	149/171 (87.1%)	294/337 (87.2%)
	Thoracic	1/82 (1.2%)	1/84 (1.2%)	2/171 (1.2%)	4/337 (1.2%)
GENERAL CO-MORBIDITIES					
Diabetes		17/82 (20.7%)	14/82 (17.1%)	26/170 (15.3%)	57/334 (17.1%)
If yes, treatment	Injected medication	6/17 (35.3%)	4/14 (28.6%)	5/26 (19.2%)	15/57 (26.3%)
	Oral medication	9/17 (52.9%)	9/14 (64.3%)	15/26 (57.7%)	33/57 (57.9%)
	Diet only	2/17 (11.8%)	1/14 (7.1%)	6/26 (23.1%)	9/57 (15.8%)
Ischaemic heart disease		9/82 (11.0%)	9/82 (11.0%)	10/170 (5.9%)	28/334 (8.4%)
Myocardial infarction within 6 months		0/82 (0.0%)	0/82 (0.0%)	0/170 (0.0%)	0/334 (0.0%)
Heart failure		2/82 (2.4%)	2/82 (2.4%)	3/170 (1.8%)	7/334 (2.1%)
Hypertension requiring treatment		30/82 (36.6%)	31/82 (37.8%)	66/170 (38.8%)	127/334 (38.0%)
Peripheral vascular disease		3/82 (3.7%)	1/82 (1.2%)	2/170 (1.2%)	6/334 (1.8%)
Stroke		2/82 (2.4%)	1/82 (1.2%)	3/170 (1.8%)	6/334 (1.8%)
TIA		4/82 (4.9%)	3/82 (3.7%)	3/170 (1.8%)	10/334 (3.0%)
Liver disease (exc cirrhosis)		3/82 (3.7%)	3/82 (3.7%)	7/170 (4.1%)	13/334 (3.9%)
Cirrhosis		0/82 (0.0%)	2/82 (2.4%)	3/170 (1.8%)	5/334 (1.5%)

Renal disease		4/82 (4.9%)	1/82 (1.2%)	4/170 (2.4%)	9/334 (2.7%)
If yes, stage	Stage 1	2/4 (50.0%)	0/1 (0.0%)	2/4 (50.0%)	4/9 (44.4%)
	Stage 2	1/4 (25.0%)	0/1 (0.0%)	2/4 (50.0%)	3/9 (33.3%)
	Stage 3a	0/4 (0.0%)	1/1 (100.0%)	0/4 (0.0%)	1/9 (11.1%)
	Stage 4	1/4 (25.0%)	0/1 (0.0%)	0/4 (0.0%)	1/9 (11.1%)
Condition associated with immunosuppression		3/82 (3.7%)	3/82 (3.7%)	5/170 (2.9%)	11/334 (3.3%)
Immunosuppressant drugs		3/3 (100.0%)	0/3 (0.0%)	2/5 (40.0%)	5/11 (45.5%)
Long-term steroids		1/3 (33.3%)	0/3 (0.0%)	2/5 (40.0%)	3/11 (27.3%)
Oral steroids in previous 6 months		2/3 (66.7%)	0/3 (0.0%)	4/5 (80.0%)	6/11 (54.5%)
RESPIRATORY COMORBIDITIES					
Asthma		9/82 (11.0%)	12/82 (14.6%)	21/170 (12.4%)	42/334 (12.6%)
If yes, any hospital admissions in last 6 months		0/9 (0.0%)	0/12 (0.0%)	0/21 (0.0%)	0/42 (0.0%)
Chronic pulmonary disease		2/82 (2.4%)	8/82 (9.8%)	13/170 (7.6%)	23/334 (6.9%)
If yes, any hospital admissions in last 6 months		0/2 (0.0%)	1/8 (12.5%)	0/13 (0.0%)	1/23 (4.3%)
Interstitial lung disease		1/82 (1.2%)	0/82 (0.0%)	2/170 (1.2%)	3/334 (0.9%)
If yes, any hospital admissions in last 6 months		1/1 (100.0%)	-	0/2 (0.0%)	1/3 (33.3%)
Pulmonary hypertension		0/82 (0.0%)	1/82 (1.2%)	0/170 (0.0%)	1/334 (0.3%)
If yes, any hospital admissions in last 6 months		-	0/1 (0.0%)	-	0/1 (0.0%)
Bronchiectasis		3/82 (3.7%)	1/82 (1.2%)	3/170 (1.8%)	7/334 (2.1%)
If yes, any hospital admissions in last 6 months		0/3 (0.0%)	0/1 (0.0%)	0/3 (0.0%)	0/7 (0.0%)
Obstructive sleep apnoea		7/82 (8.5%)	2/82 (2.4%)	4/170 (2.4%)	13/334 (3.9%)
If yes, any hospital admissions in last 6 months		0/7 (0.0%)	0/2 (0.0%)	0/4 (0.0%)	0/13 (0.0%)
If yes, CPAP?		3/7 (42.9%)	1/2 (50.0%)	4/4 (100.0%)	8/13 (61.5%)
If yes, any hospital admissions in last 6 months		0/3 (0.0%)	0/1 (0.0%)	0/4 (0.0%)	0/8 (0.0%)
COVID-19 (test confirmed)		11/73 (15.1%)	4/71 (5.6%)	13/149 (8.7%)	28/293 (9.6%)
If yes, any hospital admissions in last 6 months		1/11 (9.1%)	1/4 (25.0%)	0/13 (0.0%)	2/28 (7.1%)
SMOKING STATUS					
Smoking	Non-smoker	32/81 (39.5%)	32/82 (39.0%)	79/170 (46.5%)	143/333 (42.9%)
	Ex-smoker >3 months	43/81 (53.1%)	42/82 (51.2%)	72/170 (42.4%)	157/333 (47.1%)
	Ex-smoker <3mths >14days	3/81 (3.7%)	2/82 (2.4%)	5/170 (2.9%)	10/333 (3.0%)
	Current smoker	3/81 (3.7%)	6/82 (7.3%)	14/170 (8.2%)	23/333 (6.9%)
Number of years patient has smoked – median (IQR)		45.0 (30.0, 55.0)	38.5 (27.0, 50.0)	42.5 (30.0, 50.0)	40.0 (30.0, 50.0)
Number of cigarettes per day – median (IQR)		5 (1, 10)	14 (10, 20)	10 (5, 15)	10 (5, 15)

Number of cigars per day – median (IQR)		0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Number of pipes per day – median (IQR)		0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
Number of other per day – median (IQR)		0 (0, 0)	0 (0, 0)	0 (0, 0)	0 (0, 0)
E-cigarettes		3/80 (3.8%)	6/82 (7.3%)	10/170 (5.9%)	19/332 (5.7%)
CANCER / MALIGNANCY		-, (,	-, - (,	-, - (,	-, (,
Surgery for cancer		62/81 (76.5%)	62/82 (75.6%)	136/170 (80.0%)	260/333 (78.1%)
Primary or secondary tumour	Primary	57/62 (91.9%)	54/62 (87.1%)	120/136 (88.2%)	231/260 (88.8%)
,	Secondary	5/62 (8.1%)	8/62 (12.9%)	16/136 (11.8%)	29/260 (11.2%)
Site of malignancy	Lung	1/62 (1.6%)	1/62 (1.6%)	1/136 (0.7%)	3/260 (1.2%)
	Oesophagus	6/62 (9.7%)	6/62 (9.7%)	14/136 (10.3%)	26/260 (10.0%)
	Stomach	2/62 (3.2%)	1/62 (1.6%)	3/136 (2.2%)	6/260 (2.3%)
	Colon	22/62 (35.5%)	18/62 (29.0%)	29/136 (21.3%)	69/260 (26.5%)
	Rectum	4/62 (6.5%)	8/62 (12.9%)	21/136 (15.4%)	33/260 (12.7%)
	Anus	0/62 (0.0%)	2/62 (3.2%)	1/136 (0.7%)	3/260 (1.2%)
	Gall bladder	1/62 (1.6%)	1/62 (1.6%)	1/136 (0.7%)	3/260 (1.2%)
	Biliary tree	0/62 (0.0%)	1/62 (1.6%)	2/136 (1.5%)	3/260 (1.2%)
	Pancreas	10/62 (16.1%)	5/62 (8.1%)	19/136 (14.0%)	34/260 (13.1%)
	Liver	2/62 (3.2%)	2/62 (3.2%)	7/136 (5.1%)	11/260 (4.2%)
	Kidney	0/62 (0.0%)	0/62 (0.0%)	4/136 (2.9%)	4/260 (1.5%)
	Bladder	2/62 (3.2%)	4/62 (6.5%)	10/136 (7.4%)	16/260 (6.2%)
	Endometrium/Ovary	6/62 (9.7%)	8/62 (12.9%)	14/136 (10.3%)	28/260 (10.8%)
	Other	6/62 (9.7%)	5/62 (8.1%)	10/136 (7.4%)	21/260 (8.1%)
Curative or palliative	Curative	53/62 (85.5%)	56/62 (90.3%)	116/136 (85.3%)	225/260 (86.5%)
·	Palliative	0/62 (0.0%)	0/62 (0.0%)	1/136 (0.7%)	1/260 (0.4%)
	Don't know	9/62 (14.5%)	6/62 (9.7%)	19/136 (14.0%)	34/260 (13.1%)
Neo-adjuvant treatment in 6 months		23/62 (37.1%)	31/62 (50.0%)	53/136 (39.0%)	107/260 (41.2%)
If yes, radiotherapy		6/23 (26.1%)	9/31 (29.0%)	14/53 (26.4%)	29/107 (27.1%)
If yes, chemotherapy		22/23 (95.7%)	30/31 (96.8%)	52/53 (98.1%)	104/107 (97.2%)
If yes, immunotherapy		1/23 (4.3%)	1/31 (3.2%)	1/53 (1.9%)	3/107 (2.8%)
ARISCAT		,			•
ARISCAT score – mean (SD)		41.9 (7.9)	41.1 (7.1)	42.2 (7.6)	41.8 (7.6)
ARISCAT score – group	26-44	62/82 (75.6%)	62/84 (73.8%)	122/171 (71.3%)	246/337 (73.0%)
	>44	20/82 (24.4%)	22/84 (26.2%)	49/171 (28.7%)	91/337 (27.0%)

Receiving an additional prehabilitation prograss part of usual care	ramme	35/68 (51.5%)	37/74 (50.0%)	69/143 (48.3%)	141/285 (49.5%)
Nutritional status	MUST score 0	53/69 (76.8%)	55/66 (83.3%)	120/140 (85.7%)	228/275 (82.9%)
	MUST score 1-2	14/69 (20.3%)	11/66 (16.7%)	18/140 (12.9%)	43/275 (15.6%)
	MUST score >2	2/69 (2.9%)	0/66 (0.0%)	2/140 (1.4%)	4/275 (1.5%)

Missing data (Usual care, Low IMT, High IMT):

Data are presented as n/N (%), mean (SD) or median (IQR)

Abbreviations: ARISCAT=Assess Respiratory Risk in Surgical Patients in Catalonia, CPAP= Continuous positive airway pressure, IQR=Interquartile range, IMT= Inspiratory muscle training, MUST= Malnutrition Universal Screening Tool, SD=Standard deviation, TIA=Transient ischemic attack

3. Outcome Measures

Table 2 Primary and secondary outcomes

	Usual care (n=82)	Low IMT (n=84)	High IMT (n=171)	Overall (n=337)
Surgery completed	78/82	73/84	155/171	306/337
	(95.1%)	(86.9%)	(90.6%)	(90.8%)
PRIMARY OUTCOME				
Any PPC within 30 days	44/76	42/72	105/152	191/300
Ally PPC within 50 days	(57.9%)	(58.3%)	(69.1%)	(63.7%)
SECONDARY OUTCOMES				
Despiratory infaction	9/76	9/71	27/151	45/298
Respiratory infection	(11.8%)	(12.7%)	(17.9%)	(15.1%)
Respiratory failure	35/75	30/71	88/149	153/295
respiratory randre	(46.7%)	(42.3%)	(59.1%)	(51.9%)
Pleural effusion	20/77	20/71	34/149	74/297
rieurai etrusion	(26.0%)	(28.2%)	(22.8%)	(24.9%)
Atologtacis	21/77	22/71	44/151	87/299
Atelectasis	(27.3%)	(31.0%)	(29.1%)	(29.1%)
Dnoumatharay	1/77	3/70	11/148	15/295
Pneumothorax	(1.3%)	(4.3%)	(7.4%)	(5.1%)
Pronchosnosm	0/77	3/70	5/151	8/298
Bronchospasm	(0.0%)	(4.3%)	(3.3%)	(2.7%)

^a Data missing for 3 patients (0, 2, 1)

Aspiration pneumonitis		0/77	0/70	2/148	2/295
7 Spiration pricamonicis		(0.0%)	(0.0%)	(1.4%)	(0.7%)
Invasive ventilation		15/70	16/68	35/143	66/281
		(21.4%)	(23.5%)	(24.5%)	(23.5%)
Non-invasive ventilation (including continuous positive airway pressure (CPAP) and/or pressure support		3/68	4/66	18/138	25/272
(BIPAP))		(4.4%)	(6.1%)	(13.0%)	(9.2%)
Optiflow (high flow nasal oxygen therapy):					
Dranbulactically to provent a nulmanany complication		2/68	3/65	13/136	18/269
Prophylactically to prevent a pulmonary complication		(2.9%)	(4.6%)	(9.6%)	(6.7%)
		3/68	6/66	17/138	26/272
For treatment of a pulmonary complication		(4.4%)	(9.1%)	(12.3%)	(9.6%)
		0.0 (0.0,	0.0 (0.0,	0.0 (0.0,	0.0 (0.0,
Length of ICU stay 18		0.0)	0.0)	1.0)	1.0)
	On day of	59/78	55/72	111/151	225/301
Length of ICU stay - categorised	surgery	(75.6%)	(76.4%)	(73.5%)	(74.8%)
		7/78	8/72	13/151	28/301
	1 day	(9.0%)	(11.1%)	(8.6%)	(9.3%)
	2.1	6/78	4/72	8/151	18/301
	2 days	(7.7%)	(5.6%)	(5.3%)	(6.0%)
	271	5/78	3/72	15/151	23/301
	3-7 days	(6.4%)	(4.2%)	(9.9%)	(7.6%)
		1/78	2/72	4/151	7/301
	>7 days	(1.3%)	(2.8%)	(2.6%)	(2.3%)
		, 7 (5.0,	6 (4.0,	, 7 (5.0,	7 (5.0,
Length of hospital stay 24		14.0)	10.5)	12.5)	12.0)
		12/73	11/69	29/144	52/286
Antibiotic prescription		(16.4%)	(15.9%)	(20.1%)	(18.2%)
		0/69	3/67	5/138	8/274
Bronchodilator prescription		(0.0%)	(4.5%)	(3.6%)	(2.9%)
MIP measurements		(/	(/	()	,,
		81/82	81/84	167/171	329/337
MIP measured - baseline		(98.8%)	(96.4%)	(97.7%)	(97.6%)
		17/82	13/84	30/171	60/337
MIP measured - day of surgery		(20.7%)	(15.5%)	(17.5%)	(17.8%)
		(1 10,01	1-: .0,0,

	64.3	65.9	66.8 (46.8,	65.5
MIP - baseline	(47.1,	(46.2,	85.5)	(46.8,
	89.0)	87.6)	55.57	86.9)
	55.4	75.8	80.5 (57.8,	72.4
MIP - day of surgery	(46.8,	(63.0,	94.2)	(54.2,
	82.4)	102.5)	•	93.4)
MIP - change from baseline 32	1.2 (-5.6,	8.1 (4.2,	4.5 (-0.3,	4.8 (-1.7,
	16.0)	24.6)	18.9)	18.9)
Spirometry assessment				
Spirometry performed - baseline	73/82	67/84	140/171	280/337
Spirometry performed spaseline	(89.0%)	(79.8%)	(81.9%)	(83.1%)
Spirometry performed - day of surgery	16/82	12/84	28/171	56/337
Spirometry performed - day or surgery	(19.5%)	(14.3%)	(16.4%)	(16.6%)
FEV1				
FFV/4 baseline	2.8 (2.1,	2.8 (1.9,	2.7 (2.1,	2.8 (2.1,
FEV1 - baseline	3.2)	3.2)	3.5)	3.5)
FFV/4 day of average.	3.2 (2.5,	3.1 (2.0,	2.8 (2.1,	3.0 (2.3,
FEV1 - day of surgery	3.6)	3.5)	3.4)	3.5)
FFV4 shows from baseline 20	0.1 (-0.1,	-0.1 (-0.2,	0.0 (-0.2,	0.0 (-0.2,
FEV1 - change from baseline 39	0.5)	0.1)	0.1)	0.2)
FVC	·	•	•	-
	3.9 (3.1,	3.8 (2.8,	3.6 (3.0,	3.7 (3.0,
FVC - baseline	4.5)	4.5)	4.6)	4.5)
	4.1 (3.6,	4.0 (3.1,	3.8 (3.1,	3.9 (3.3,
FVC - day of surgery	4.6)	4.7)	4.5)	4.6)
	-0.0 (-0.1,	-0.0 (-0.1,	-0.0 (-0.2,	-0.0 (-0.1,
FVC - change from baseline 43	0.1)	0.1)	0.2)	0.1)
Training load	,	,	<u> </u>	,
=		77/40	30.6	23.1
Training load - baseline 45		7.7 (4.0)	(14.0)	(15.9)
T	·	0.2 (4.0)	39.9	29.8
Training load - day of surgery 46	55.0 ()	8.3 (4.8)	(18.7)	(21.5)
Training load - change from baseline 47		0.6 (4.3)	9.3 (14.0)	6.5 (12.4)
Mortality				
In-hospital mortality	0/78	0/73	0/155	0/306
in-nospital mortality	(0.0%)	(0.0%)	(0.0%)	(0.0%)

30-day mortality	1/78 (1.3%)	0/73 (0.0%)	0/155 (0.0%)	1/306 (0.3%)
Complications of surgery				
Comprehensive Classification Index 52	12.2 (0.0,	0.0 (0.0,	12.2 (0.0,	8.7 (0.0,
comprehensive classification mack 32	27.2)	29.6)	29.6)	29.6)

Missing data (Usual care, Low IMT, High IMT): 18*Data missing for 5 patients (0, 1, 4). 24*Data missing for 4 patients (0, 1, 3). 32*Data missing for 1 patients (0, 0, 1). 39*Data missing for 3 patients (0, 0, 3). 43*Data missing for 3 patients (0, 0, 3). 45*Data missing for 99 patients (82, 6, 11). 46*Data missing for 131 patients (81, 18, 32). 47*Data missing for 139 patients (82, 19, 38). 52*Data missing for 33 patients (4, 11, 18).

4. Adverse Events

Table 3 Expected and anticipated adverse and serious adverse events, by trial allocation

	Usual Ca	re (n=82)	Low IM	T (n=84)	High IM	「 (n=171)	Overall	(n=337)
	All events	SAEs						
	Events/Patients							
Expected events of	IMT (during training)							
Any event	3/2 (2.4%)	0/0 (0.0%)	19/11 (13.1%)	0/0 (0.0%)	50/24 (14.0%)	0/0 (0.0%)	72/37 (11.0%)	0/0 (0.0%)
Headache	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	5/5 (2.9%)	0/0 (0.0%)	5/5 (1.5%)	0/0 (0.0%)
Dizziness	1/1 (1.2%)	0/0 (0.0%)	8/4 (4.8%)	0/0 (0.0%)	11/10 (5.8%)	0/0 (0.0%)	20/15 (4.5%)	0/0 (0.0%)
Nausea	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	5/5 (2.9%)	0/0 (0.0%)	6/6 (1.8%)	0/0 (0.0%)
Chest discomfort	1/1 (1.2%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	7/7 (4.1%)	0/0 (0.0%)	10/10 (3.0%)	0/0 (0.0%)
Bronchospasm	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Cough	1/1 (1.2%)	0/0 (0.0%)	3/3 (3.6%)	0/0 (0.0%)	9/8 (4.7%)	0/0 (0.0%)	13/12 (3.6%)	0/0 (0.0%)
Epistaxis	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Pain	0/0 (0.0%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	5/5 (2.9%)	0/0 (0.0%)	7/7 (2.1%)	0/0 (0.0%)
Other	0/0 (0.0%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	7/4 (2.3%)	0/0 (0.0%)	9/6 (1.8%)	0/0 (0.0%)
Anticipated events	of surgery & adjuvan	t chemo/radiother	apy (post-operativ	e)				
Any event	128/46 (56.1%)	22/7 (8.5%)	122/34 (40.5%)	25/7 (8.3%)	309/91 (53.2%)	54/19 (11.1%)	559/171 (50.7%)	101/33 (9.8%)
Myocardial								_
infarction	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	1/1 (1.2%)	1/1 (0.6%)	0/0 (0.0%)	2/2 (0.6%)	1/1 (0.3%)
Cardiac arrest								
(requiring	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	1/1 (0.3%)

resuscitation involving ventricular defibrillation/direct current shock)								
Cardiac arrest								
(requiring								
external/internal	4 /4 /4 20/)	4 /4 /4 20/)	0/0/0.00()	0/0/0.00()	4 /4 /0 (0/)	1 (1 (0 (0))	2/2/0.6%	2/2/0.69()
cardiac massage) Haemodynamic	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	1/1 (0.6%)	2/2 (0.6%)	2/2 (0.6%)
support (requiring								
use of any inotropes)	18/18 (22.0%)	1/1 (1.2%)	10/10 (11.9%)	2/2 (2.4%)	31/31 (18.1%)	2/2 (1.2%)	59/59 (17.5%)	5/5 (1.5%)
Haemodynamic	, , ,	, , ,	, , ,	, , ,	, , ,	, , ,	, , ,	, , ,
support (requiring								
use of pulmonary								
artery catheter)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Haemodynamic								
support (requiring	1/1/1 20/)	0/0/0.00()	0/0/0.00()	0/0/0.00()	C/C/2 F0/\	0/0/0.00()	7/7/2 40/\	0/0/0.00()
use of vasodilator)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	6/6 (3.5%)	0/0 (0.0%)	7/7 (2.1%)	0/0 (0.0%)
Arrhythmia	10/10 (12.2%)	0/0 (0.0%)	6/6 (7.1%)	0/0 (0.0%)	20/18 (10.5%)	3/3 (1.8%)	36/34 (10.1%)	3/3 (0.9%)
Pacing	4/4 (4.9%)	0/0 (0.0%)	3/3 (3.6%)	0/0 (0.0%)	7/7 (4.1%)	3/3 (1.8%)	14/14 (4.2%)	3/3 (0.9%)
Bleeding	1/1 (1.2%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	2/2 (1.2%)	2/2 (1.2%)	4/4 (1.2%)	2/2 (0.6%)
Deep vein	0/0/0.00()	0 (0 (0 00()	4 /4 /4 20/)	4 /4 /4 20/)	1/1/0.69()	1/1/0.00()	2/2/0.69()	2/2/0.69()
thrombosis	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	1/1 (1.2%)	1/1 (0.6%)	1/1 (0.6%)	2/2 (0.6%)	2/2 (0.6%)
Pulmonary embolus Intubation / re-	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	2/2 (1.2%)	1/1 (0.6%)	3/3 (0.9%)	1/1 (0.3%)
intubation &								
ventilation	1/1 (1.2%)	1/1 (1.2%)	2/2 (2.4%)	1/1 (1.2%)	6/6 (3.5%)	3/3 (1.8%)	9/9 (2.7%)	5/5 (1.5%)
Tracheostomy	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	1/1 (0.6%)	1/1 (0.3%)	1/1 (0.3%)
Initiation of mask	0,0 (0.070)	0,0 (0.070)	0,0 (0.070)	0,0 (0.070)	1,1 (0.070)	1,1 (0.070)	2,2 (0.070)	1,1 (0.570)
continuous positive								
airway pressure	3/3 (3.7%)	1/1 (1.2%)	3/3 (3.6%)	1/1 (1.2%)	11/11 (6.4%)	2/2 (1.2%)	17/17 (5.0%)	4/4 (1.2%)
Acute respiratory	, ,		, , ,		, , ,		. , ,	. , ,
distress syndrome	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (1.2%)	1/1 (0.6%)	2/2 (0.6%)	1/1 (0.3%)
Pneumothorax	0/0 (0.0%)	0/0 (0.0%)	4/4 (4.8%)	2/2 (2.4%)	8/8 (4.7%)	2/2 (1.2%)	12/12 (3.6%)	4/4 (1.2%)
Acute respiratory								
failure	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	6/6 (3.5%)	3/3 (1.8%)	7/7 (2.1%)	4/4 (1.2%)

Pneumonia Atelectasis /	1/1 (1.2%)	0/0 (0.0%)	3/3 (3.6%)	1/1 (1.2%)	16/16 (9.4%)	4/4 (2.3%)	20/20 (5.9%)	5/5 (1.5%)
pulmonary collapse	12/12 (14.6%)	2/2 (2.4%)	16/15 (17.9%)	3/3 (3.6%)	40/40 (23.4%)	3/3 (1.8%)	68/67 (19.9%)	8/8 (2.4%)
Prolonged air leak	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	1/1 (0.3%)
Chylothorax	1/1 (1.2%)	1/1 (1.2%)	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (0.6%)	2/2 (0.6%)
Pleural effusion	11/11 (13.4%)	2/2 (2.4%)	19/17 (20.2%)	3/3 (3.6%)	28/26 (15.2%)	3/3 (1.8%)	58/54 (16.0%)	8/8 (2.4%)
Acute aspiration	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Urinary retention	3/3 (3.7%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	6/6 (3.5%)	1/1 (0.6%)	10/10 (3.0%)	1/1 (0.3%)
Acute kidney injury	9/9 (11.0%)	0/0 (0.0%)	5/5 (6.0%)	0/0 (0.0%)	10/10 (5.8%)	3/3 (1.8%)	24/24 (7.1%)	3/3 (0.9%)
New haemofiltration			, ,		, ,		. , ,	, , ,
/ dialysis	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (1.2%)	1/1 (0.6%)	2/2 (0.6%)	1/1 (0.3%)
Retained or								
fractured ureteric								
stent	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	2/2 (0.6%)	0/0 (0.0%)
GI bleed	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	2/2 (0.6%)	0/0 (0.0%)
Perforation	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (1.2%)	0/0 (0.0%)	2/2 (0.6%)	0/0 (0.0%)
Intra-abdominal								
haematoma	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (1.2%)	1/1 (0.6%)	2/2 (0.6%)	1/1 (0.3%)
Leak from any								
anastomosis, staple								
line, or localised	. (. ()	. /. /	0 (0 (0 00))	0 (0 (0 .0))	. (2. (4. 22.))	0 (0 (4 00))	/ / / .	0 (= (
conduit necrosis	4/4 (4.9%)	1/1 (1.2%)	3/3 (3.6%)	2/2 (2.4%)	4/3 (1.8%)	3/2 (1.2%)	11/10 (3.0%)	6/5 (1.5%)
lleus	5/5 (6.1%)	0/0 (0.0%)	4/4 (4.8%)	1/1 (1.2%)	7/7 (4.1%)	1/1 (0.6%)	16/16 (4.7%)	2/2 (0.6%)
Feeding J-tube	0 (0 (0 00))	0/0/0 00/	4 (4 (4 00))	4/4/4/2001	0 (0 (0 00))	0 (0 (0 00))	4 (4 (0 00))	4 /4 /0 00/)
complication	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	1/1 (0.3%)
Delayed gastric	2/2/2/40/\	0/0 (0.0%)	2/2 (2.4%)	2/2 (2.4%)	1/1 (0.6%)	1/1/0.69/\	5/5 (1.5%)	2/2/0.00/\
emptying Ascites	2/2 (2.4%) 0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (2.4%) 0/0 (0.0%)		1/1 (0.6%) 0/0 (0.0%)		3/3 (0.9%)
		, , ,		,	2/2 (1.2%)	, , ,	2/2 (0.6%)	0/0 (0.0%)
Liver dysfunction New onset diabetes	0/0 (0.0%)	0/0 (0.0%) 0/0 (0.0%)	1/1 (1.2%) 0/0 (0.0%)	0/0 (0.0%) 0/0 (0.0%)	4/4 (2.3%)	0/0 (0.0%) 0/0 (0.0%)	5/5 (1.5%)	0/0 (0.0%) 0/0 (0.0%)
Surgical wound	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
infection	3/3 (3.7%)	1/1 (1.2%)	2/2 (2.4%)	0/0 (0.0%)	5/5 (2.9%)	0/0 (0.0%)	10/10 (3.0%)	1/1 (0.3%)
Sepsis	2/2 (2.4%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	3/3 (1.8%)	0/0 (0.0%)	6/6 (1.8%)	0/0 (0.0%)
Urinary tract	2/2 (2.4/0)	0/0 (0.070)	1/1 (1.2/0)	0/0 (0.070)	3/3 (1.0/0)	0/0 (0.070)	0/0 (1.0/0)	0/0 (0.0/0)
infection	1/1 (1.2%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	4/4 (1.2%)	0/0 (0.0%)
Other infections	3/3 (3.7%)	0/0 (0.0%)	4/4 (4.8%)	1/1 (1.2%)	6/6 (3.5%)	1/1 (0.6%)	13/13 (3.9%)	2/2 (0.6%)
Care infections	3,3 (3.770)	0,0 (0.0/0)	777 (7.070)	±, ± (±.2/0)	0,0 (3.5/0)	1, 1 (0.070)	13, 13 (3.370)	2,2 (0.0/0)

Danisan and atmalia	1/1/1/20/)	1 /1 /1 20/\	4 /4 /4 20/\	0/0/0 00/)	2/2/4 00/	1/1/0.00()	F/F/4 F0/\	2/2/0.00()
Permanent stroke	1/1 (1.2%)	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	3/3 (1.8%)	1/1 (0.6%)	5/5 (1.5%)	2/2 (0.6%)
Other neurological	1/1/1 20/)	1 /1 /1 20/\	0/0/0 00/	0/0/0.00()	1/1/0/00	0/0/0.00/	2/2/0.00()	1 /1 (0.20/)
injury	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	2/2 (0.6%)	1/1 (0.3%)
Confusion / Delirium	2/2 (2.4%)	0/0 (0.0%)	4/4 (4.8%)	0/0 (0.0%)	16/16 (9.4%)	0/0 (0.0%)	22/22 (6.5%)	0/0 (0.0%)
Acute psychosis /	0/0/0 00/0	0.40.40.004	4 /4 /4 20/)	0 (0 (0 00))	0 (0 (0 00))	0/0/0 00/	4 (4 (0 00))	0.40.40.004)
delirium	0/0 (0.0%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Re-operation due to	4/4/4 00()	2/2/2 40/	0/0/0.00()	0/0/0.00()	4/2 /4 00/)	2/2/4/20/	0 /7 /2 40/)	5 /4 /4 20/)
any cause	4/4 (4.9%)	2/2 (2.4%)	0/0 (0.0%)	0/0 (0.0%)	4/3 (1.8%)	3/2 (1.2%)	8/7 (2.1%)	5/4 (1.2%)
Disease recurrence /	. /. /	0 (0 (0 00))	2/2/2 22/1	0 (0 (0 00))	0 (0 (0 00))	2/2/2 22/	. (. ()	2/2/2 22/2
progression	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Wound dehiscence	3/3 (3.7%)	2/2 (2.4%)	2/2 (2.4%)	0/0 (0.0%)	4/4 (2.3%)	1/1 (0.6%)	9/9 (2.7%)	3/3 (0.9%)
Incisional hernia	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Conversion from								
minimal access								
surgery to open								
surgery	1/1 (1.2%)	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	3/3 (1.8%)	0/0 (0.0%)	5/5 (1.5%)	1/1 (0.3%)
Chyle leak / chylous								
ascites	4/4 (4.9%)	1/1 (1.2%)	1/1 (1.2%)	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	5/5 (1.5%)	2/2 (0.6%)
Bleeding (requiring								
transfusion)	5/5 (6.1%)	1/1 (1.2%)	3/3 (3.6%)	0/0 (0.0%)	12/12 (7.0%)	0/0 (0.0%)	20/20 (5.9%)	1/1 (0.3%)
Bronchospasm	1/1 (1.2%)	0/0 (0.0%)	1/1 (1.2%)	0/0 (0.0%)	2/2 (1.2%)	0/0 (0.0%)	4/4 (1.2%)	0/0 (0.0%)
Aspiration								
pneumonitis	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	1/1 (0.6%)	1/1 (0.3%)	1/1 (0.3%)
Anaemia	2/2 (2.4%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	3/3 (1.8%)	0/0 (0.0%)	5/5 (1.5%)	0/0 (0.0%)
Thrombocytopenia	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	0/0 (0.0%)	1/1 (0.3%)	0/0 (0.0%)
Nausea	1/1 (1.2%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	4/4 (2.3%)	0/0 (0.0%)	7/7 (2.1%)	0/0 (0.0%)
Vomiting	1/1 (1.2%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	3/3 (1.8%)	0/0 (0.0%)	6/6 (1.8%)	0/0 (0.0%)
Constipation	0/0 (0.0%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (0.6%)	0/0 (0.0%)
Sepsis	1/1 (1.2%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	1/1 (0.6%)	1/1 (0.6%)	2/2 (0.6%)	1/1 (0.3%)
Respiratory infection	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	3/3 (1.8%)	0/0 (0.0%)	3/3 (0.9%)	0/0 (0.0%)
Elevated AST / ALT	0/0 (0.0%)	0/0 (0.0%)	2/2 (2.4%)	0/0 (0.0%)	0/0 (0.0%)	0/0 (0.0%)	2/2 (0.6%)	0/0 (0.0%)
	-, - ()	-, - ()	-, - ()	-, - (-:-, -)	-, -	-, - ()	=, = ()	3, 2 (2.2.2)

Notes:

Data are presented as events/patients (%)

Abbreviations: IMT= Inspiratory muscle training, SAE=Serious adverse event